Skip to main content Accessibility help
×
Home

An open trial of Omega-3 fatty acids for depression in pregnancy*

  • Marlene P. Freeman (a1) (a2), Joseph R. Hibbeln (a3), Katherine L. Wisner (a4), Marcy Watchman (a1) (a2) and Alan J. Gelenberg (a2)...

Abstract

Objective:

In this flexible-dose, open-label trial, we examined the efficacy of omega-3 fatty acids for the treatment of depression during pregnancy.

Methods:

Fifteen pregnant women with major depressive episodes participated. Subjects initially received two capsules per day [0.93 g of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)]; the dose could be increased by one capsule per day every 2 weeks to a maximal dose of 2.8 g. Subjects were assessed with the Edinburgh Postnatal Depression Scale (EPDS) and Hamilton Rating Scale for Depression (HRSD).

Results:

Average duration of participation in this treatment trial was 8.3 weeks (SD ± 7.1). Average final dose of EPA + DHA in this flexible dose trial was 1.9 g per day (±0.5). The mean reduction in EPDS scores was 40.9% (SD ± 21.9); the mean decrease in HRSD score was 34.1% (SD ± 27.1).

Conclusions:

This open trial provides data to support the need for randomized controlled dose-finding trials of omega-3 fatty acids in major depressive episodes during pregnancy.

Copyright

Corresponding author

Marlene P. Freeman, Women's Mental Health Program, Department of Psychiatry, University of Arizona College of Medicine, 1501 N. Campbell Avenue, PO Box 245002, Tucson, AZ 85724-5002, USA. Tel: +1 520 626 6509; Fax: +1 520 626 6050; E-mail: marlenef@email.arizona.edu

References

Hide All
1.Evans, J, Heron, J, Francomb, H, Oke, S, Golding, J. Cohort study of depressed mood during pregnancy and after childbirth. BMJ 2001;323: 257260.
2.Wadhwa, PD, Sandman, CA, Porto, M, Dunkel-Schetter, C, Garite, TJ. The association between prenatal stress and infant birth weight and gestational age at birth: a prospective investigation. Am J Obstet Gynecol 1993;169: 858865.
3.Istvan, J. Stress, anxiety, and birth outcomes: a critical review of the evidence. Psychol Bull 1986;100: 331348.
4.Costei, AM, Kozer, E, Ho, T, Ito, S, Koren, G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002;156 (1): 11291132.
5.Mohan, CG, Moore, JJ. Fluoxetine toxicity in a preterm infant. J Perinatol 2000;20 (7):445446.
6.Nordeng, H, Lindemann, R, Perminov, KV, Reikvam, A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 2001;90 (3):288291.
7.Cohen, LS, Heller, VL, Bailey, JW, Grush, L, Ablon, JS, Bouffard, SM. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 2000;48 (10):9961000.
8.Otto, SJ, Van Houwelingen, AC, Antal, Met al. Maternal and neonatal essential fatty acid status in phospholipids: an international comparative study. Eur J Clin Nutr 1997;51: 232242.
9.Min, Y, Ghebremeskel, K, Crawford, MAet al. Pregnancy reduces arachidonic and docosahexaenoic in plasma triacylglycerols of Korean women. Int J Vitam Nutr Res 2000;70: 7075.
10.Holman, RT, Johnson, SB, Ogburn, PL. Deficiency of essential fatty acids and membrane fluidity during pregnancy and lactation. Proc Natl Acad Sci USA 1991;88: 48354839.
11.Benisek, D, Shabert, J, Skornik, R. Dietary intake of polyunsaturated fatty acids by pregnant or lactating women in the United States. Obstet Gynecol 2000;95: 7778.
12.Araya, J, Rojas, M, Fernandez, P, Matenluna, A. Essential fatty acid content of maternal erythrocyte phospholipids. A study in pertern and full-term human newborns. Rev Med Chil 1998;126: 391396.
13.Olsen, SF, Sorensen, JD, Secher, NJet al. Randomised controlled trial of effect of fish oil supplementation on pregnancy duration. Lancet 1992;339: 10031004.
14.Williams, MA, Zingham, RW, King, IB, Zebelman, AM. Omega-3 fatty acids in maternal erythrocytes and risk of preeclampsia. Epidemiology 1995;6: 232237.
15.Petridou, E, Koussouri, M, Toupadaki, Net al. Diet during pregnancy and the risk of cerebral palsy. Br J Nutr 1998;79: 407412.
16.Hoffman, DR, Uauy, R. Essentiality of dietary n-3 fatty acids for premature infants: plasma and red blood cell fatty acid composition. Lipids 1992;27: 886895.
17.Foreman-Van Drongelen, M, Van Houwelingen, AC, Kester, ADM, Blanco, CE, Hasaart, THM, Hornstra, G. Influence of feeding artificial-formula milks containing docohexaenoic and arachidonic acids on the postnatal long-chain polyunsaturated fatty acid status of healthy preterm infants. Br J Nutr 1996;76: 649667.
18.ISSFAL Board Of Directors. Recommendations for the essential fatty acid requirement for infant formula. ISSFAL Newsletter 1994;1: 45.
19.FAO/WHO Expert Committee. The role of essential fatty acids in neural development: implications for perinatal nutrition. Am J Clin Nutr 1994;57: 703710.
20.Aggett, PJ, Haschke, F, Heine, Wet al. ESPGAN comment of the content and composition of lipids in infant formula. Acta Paediatr Scand 1991;80: 887896.
21.British Nutrition Foundation. Unsaturated fatty acids: nutritional and physiologycal significance. London: Chapman & Hall, 1992.
22.Hibbeln, JR. Seafood consumption, the DHA content of mothers' milk and prevalence rates of postpartum depression: a cross-national, ecological analysis. J Affect Disord 2002;69: 1529.
23.De Vriese, SR, Christophe, AB, Maes, M. Lowered serum n-3 polyunsaturated fatty acid (PUFA) levels predict the occurrence of postpartum depression: further evidence that lowered n-PUFAs are related to major depression. Life Sci 2003;73 (25):31813187.
24.Horrobin, DF, Peet, M. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002;59 (10):913919.
25.Nemets, B, Stahl, Z, Belmaker, RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002;159: 477479.
26.Su, KP, Huang, SY, Chiu, CCet al. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 2003;13: 267271.
27.Marangell, LB, Martinez, JM, Zboyan, HA, Kertz, B, Kim, HF, Puryear, LJ. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 2003;160 (5):996998.
28.Chiu, CC, Huang, SY, Shen, WW, Su, KP. Omega-3 fatty acids for depression in pregnancy. Am J Psychiatry 2003;160 (2):385.
29.Eritsland, J, Arnesen, H, Seljeflot, I, Kierulf, P. Long-term effects of n-3 polyunsaturated fatty acids on haemostatic variables and bleeding episodes in patients with coronary artery disease. Blood Coagul Fibrinolysis 1995;6 (1):1722.
30.Mueller, BA, Talbert, RL, Tegeler, CH, Prihoda, TJ. The bleeding time effects of a single dose of aspirin in subjects receiving omega-3 fatty acid dietary supplementation. J Clin Pharmacol 1991;31 (2):185190.
31.Buckley, MS, Goff, AD, Knapp, WE. Fish oil interaction with warfarin. Ann Pharmacother 2004;38 (1): 5052.
32.Eisenberg, DM, Davis, RB, Ettner, SLet al. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 1998;280 (18):15691575.

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed